Musrelan (Suxamethonium Chloride Dihydrate)

Suxamethonium chloride, the active ingredient in Musrelan, is a depolarizing neuromuscular blocker presented as a sterile injectable solution for intravenous use. It provides rapid, short‑acting muscle relaxation to facilitate endotracheal intubation, support surgical procedures, and enable certain diagnostic examinations.

GNH USA supplies Musrelan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, ensuring quality assurance and reliable global distribution. The company adheres to stringent regulatory standards and provides comprehensive logistics support for timely delivery.

Musrelan, a depolarizing neuromuscular blocker, acts on the nicotinic acetylcholine receptors at the neuromuscular junction to produce short‑lasting paralysis.

- Facilitation of endotracheal intubation: Provides rapid muscle relaxation to allow safe placement of the airway tube. - Muscle relaxation during surgery: Enables controlled paralysis for optimal surgical conditions and ventilation management. - Diagnostic procedures requiring short‑acting paralysis: Allows brief neuromuscular blockade for procedures such as electrodiagnostic testing.

Adverse reactions to Musrelan may vary in frequency and severity.

Common Side Effects: - Hyperkalemia: Transient rise in serum potassium levels. - Bradycardia: Slowed heart rate, especially in pediatric patients. - Increased intra‑ocular pressure: May affect ophthalmic procedures. - Transient fasciculations: Brief muscle twitches before paralysis.

Serious or Rare Side Effects: - Malignant hyperthermia: Life‑threatening hypermetabolic crisis. - Prolonged apnea: Extended respiratory paralysis requiring ventilation. - Anaphylaxis: Severe allergic reaction with hypotension and airway compromise. - Cardiac arrest: Sudden loss of cardiac function, often linked to severe hyperkalemia.

When using Musrelan, clinicians should observe several precautionary measures to minimize risk.

- Assess patient history: Verify absence of known susceptibility to malignant hyperthermia or hyperkalemia. - Monitor electrolytes: Check serum potassium levels before and after administration. - Cardiac monitoring: Continuously observe heart rate and rhythm during and after dosing. - Adjust dose in renal impairment: Reduce amount in patients with significant renal dysfunction. - Store at ambient temperature: Keep below 25°C, protect from light and moisture in original packaging.

Musrelan can interact with other agents that affect neuromuscular transmission or potassium balance.

Major Interactions (Avoid): - Potassium‑sparing diuretics: May exacerbate hyperkalemia. - Non‑depolarizing neuromuscular blockers: Can potentiate paralysis.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: Enhance neuromuscular blockade. - Inhalational anesthetics: May increase risk of malignant hyperthermia. - Anticholinesterases: Can prolong or intensify the block.